{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:31:04Z","timestamp":1787142664676,"version":"build-2736575974"},"reference-count":32,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003748","name":"Svenska S?llskapet f?r Medicinsk Forskning","doi-asserted-by":"publisher","award":["PG-22-0350-H-01"],"award-info":[{"award-number":["PG-22-0350-H-01"]}],"id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["2023.0073"],"award-info":[{"award-number":["2023.0073"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["2023.0512"],"award-info":[{"award-number":["2023.0512"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["22 2203 Pj 01 H"],"award-info":[{"award-number":["22 2203 Pj 01 H"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["23 0650 JIA"],"award-info":[{"award-number":["23 0650 JIA"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["23 2747 Pj"],"award-info":[{"award-number":["23 2747 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Research Council (VR)","award":["2020-04478"],"award-info":[{"award-number":["2020-04478"]}]},{"name":"Swedish Research Council (VR)","award":["2022-01519"],"award-info":[{"award-number":["2022-01519"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study investigates how the structural design of secondary PNA probes affects their ability to carry the cytotoxic agent DM1 in a novel affibody-PNA-based pretargeting approach directed at Human Epidermal growth factor Receptor 2 (HER2)-expressing cells. Six different DM1-conjugated secondary 8-mer PNA probes with strategic hydrophilic modifications were designed and evaluated. Surface plasmon resonance analysis confirmed that the modifications preserved hybridization to the HER2-targeting affibody-PNA primary probe, with all secondary probes showing similar binding kinetics (KD = 310\u2013660 pM). Biodistribution studies in nontumor-bearing NMRI mice with lutetium-177 (177Lu)-labeled secondary probes revealed that probe modifications dramatically influenced organ distribution patterns. The secondary probes SP2, SP5, and SPc demonstrated favorable biodistribution profiles with reduced accumulation in critical organs, i.e., liver and kidneys. Receptor-mediated endocytosis was also affected by secondary probe design, showing an increase in cellular internalization for SP5 (20.4% after 24 h) compared to SP2 (12.1%). Our findings highlight how rational design can optimize in vivo pharmacokinetics while preserving binding properties essential for effective pretargeting, providing a foundation for developing novel targeted cytotoxic delivery systems with potentially improved therapeutic indexes.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.6c00035","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:22:43Z","timestamp":1785849763000},"page":"1562-1570","source":"Crossref","is-referenced-by-count":0,"title":["Peptide\nNucleic Acid Probes for Pretargeted Affibody-Mediated\nDelivery of Cytotoxic Payloads to HER2-Positive Carcinoma"],"prefix":"10.1021","volume":"37","author":[{"given":"Jacob","family":"Clinton","sequence":"first","affiliation":[{"name":"KTH Royal Institute of Technology , , ,","place":["Stockholm, Sweden, 10691"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Westerlund","sequence":"additional","affiliation":[{"name":"KTH Royal Institute of Technology , , ,","place":["Stockholm, Sweden, 10691"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Haraldsson","sequence":"additional","affiliation":[{"name":"KTH Royal Institute of Technology , , ,","place":["Stockholm, Sweden, 10691"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebba","family":"Norde\u0301n","sequence":"additional","affiliation":[{"name":"KTH Royal Institute of Technology , , ,","place":["Stockholm, Sweden, 10691"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilde","family":"Hagelin","sequence":"additional","affiliation":[{"name":"Uppsala University , , ,","place":["Uppsala, Sweden, 75185"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5340-8618","authenticated-orcid":true,"given":"Eleftherios","family":"Papalanis","sequence":"additional","affiliation":[{"name":"Uppsala University , , ,","place":["Uppsala, Sweden, 75185"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeen","family":"Ud-din","sequence":"additional","affiliation":[{"name":"Uppsala University , , ,","place":["Uppsala, Sweden, 75185"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4778-3909","authenticated-orcid":true,"given":"Anzhelika","family":"Vorobyeva","sequence":"additional","affiliation":[{"name":"Uppsala University , , ,","place":["Uppsala, Sweden, 75185"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5391-600X","authenticated-orcid":true,"given":"Torbjo\u0308rn","family":"Gra\u0308slund","sequence":"additional","affiliation":[{"name":"KTH Royal Institute of Technology , , ,","place":["Stockholm, Sweden, 10691"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0695-5188","authenticated-orcid":true,"given":"Amelie","family":"Eriksson Karlstro\u0308m","sequence":"additional","affiliation":[{"name":"KTH Royal Institute of Technology , , ,","place":["Stockholm, Sweden, 10691"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2660-9837","authenticated-orcid":true,"given":"Maryam","family":"Oroujeni","sequence":"additional","affiliation":[{"name":"Uppsala University , , ,","place":["Uppsala, Sweden, 75185"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"2026081907205019300_cit1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical\nefficacy of FDA-approved antibody\u2013drug conjugates in human\ncancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"2026081907205019300_cit2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620915058","article-title":"Risk of\nhepatotoxicity\nwith trastuzumab emtansine in breast cancer patients: a systematic\nreview and meta-analysis","volume":"11","author":"Cobert","year":"2020","journal-title":"Ther. Adv. Drug Saf."},{"key":"2026081907205019300_cit3","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-01820-z","article-title":"Maytansinoids in cancer\ntherapy: advancements in antibody-drug conjugates and nanotechnology-enhanced\ndrug delivery systems","volume":"16","author":"Perra","year":"2025","journal-title":"Discover Oncol."},{"key":"2026081907205019300_cit4","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver\nInjury [Internet]. Bethesda (MD), National\nInstitute of Diabetes and Digestive and Kidney Diseases2012https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK600083\/. [Updated Jan 30, 2024]."},{"key":"2026081907205019300_cit5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1146\/annurev-pharmtox-010818-021118","article-title":"Engineered Protein\nScaffolds as Next-Generation Therapeutics","volume":"60","author":"Gebauer","year":"2020","journal-title":"Annu.\nRev. Pharmacol. Toxicol."},{"key":"2026081907205019300_cit6","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1039\/D2CB00094F","article-title":"Protein scaffolds:\nantibody alternatives for cancer\ndiagnosis and therapy","volume":"3","author":"Luo","year":"2022","journal-title":"RSC Chem. Biol."},{"key":"2026081907205019300_cit7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jconrel.2018.08.040","article-title":"Affibody-derived drug conjugates:\nPotent cytotoxic molecules for treatment of HER2 over-expressing tumors","volume":"288","author":"Altai","year":"2018","journal-title":"J. Controlled Release"},{"key":"2026081907205019300_cit8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010085","article-title":"Drug Conjugates Based on a Monovalent\nAffibody Targeting Vector Can Efficiently Eradicate HER2 Positive\nHuman Tumors in an Experimental Mouse Model","volume":"13","author":"Xu","year":"2021","journal-title":"Cancers"},{"key":"2026081907205019300_cit9","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13030430","article-title":"Affibody-Derived Drug Conjugates\nTargeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution","volume":"13","author":"Ding","year":"2021","journal-title":"Pharmaceutics."},{"key":"2026081907205019300_cit10","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jconrel.2023.02.005","article-title":"Comparison\nof HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived\ndrugs","volume":"355","author":"Yin","year":"2023","journal-title":"J. Controlled Release"},{"key":"2026081907205019300_cit11","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13111974","article-title":"The Influence of Domain Permutations\nof an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug\nConjugate on Tumor Cell Proliferation and Therapy Efficacy","volume":"13","author":"Yin","year":"2021","journal-title":"Pharmaceutics."},{"key":"2026081907205019300_cit12","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.2967\/jnumed.121.262186","article-title":"Pretargeting:\nA Path Forward for Radioimmunotherapy","volume":"63","author":"Cheal","year":"2022","journal-title":"J. Nucl.\nMed."},{"key":"2026081907205019300_cit13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.7150\/thno.12766","article-title":"Feasibility\nof Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting\nof Malignant Tumors","volume":"6","author":"Honarvar","year":"2016","journal-title":"Theranostics"},{"key":"2026081907205019300_cit14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.07.003","article-title":"Evaluation\nof affibody molecule-based PNA-mediated\nradionuclide pretargeting: Development of an optimized conjugation\nprotocol and 177Lu labeling","volume":"54","author":"Altai","year":"2017","journal-title":"Nucl.\nMed. Biol."},{"key":"2026081907205019300_cit15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030500","article-title":"Comparative Evaluation of Novel 177Lu-Labeled\nPNA Probes for Affibody-Mediated PNA-Based Pretargeting","volume":"13","author":"Tano","year":"2021","journal-title":"Cancers"},{"key":"2026081907205019300_cit16","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1021\/acsptsci.4c00106","article-title":"Shorter Peptide Nucleic Acid Probes Improve Affibody-Mediated\nPeptide Nucleic Acid-Based Pretargeting","volume":"7","author":"Westerlund","year":"2024","journal-title":"ACS\nPharmacol. Transl. Sci."},{"key":"2026081907205019300_cit17","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.2967\/jnumed.118.208348","article-title":"Radionuclide Therapy of HER2-Expressing Human Xenografts\nUsing Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In\nVivo Proof of Principle","volume":"59","author":"Westerlund","year":"2018","journal-title":"J. Nucl. Med."},{"key":"2026081907205019300_cit18","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.2967\/jnumed.121.262123","article-title":"Affibody-Mediated\nPNA-Based Pretargeted Cotreatment\nImproves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing\nXenografts","volume":"63","author":"Oroujeni","year":"2022","journal-title":"J. Nucl. Med."},{"key":"2026081907205019300_cit19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing\nhydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics\nand therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"2026081907205019300_cit20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1158\/1535-7163.MCT-16-0343","article-title":"Optimization of\na PEGylated Glucuronide-Monomethylauristatin\nE Linker for Antibody-Drug Conjugates","volume":"16","author":"Burke","year":"2017","journal-title":"Mol.\nCancer Ther."},{"key":"2026081907205019300_cit21","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1039\/D2SC05678J","article-title":"Compact\nhydrophilic electrophiles enable highly efficacious high DAR ADCs\nwith excellent in vivo PK profile","volume":"14","author":"Ochtrop","year":"2023","journal-title":"Chem. Sci."},{"key":"2026081907205019300_cit22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2967\/jnumed.110.083592","article-title":"Molecular design and optimization of 99mTc-labeled\nrecombinant affibody molecules improves their biodistribution and\nimaging properties","volume":"52","author":"W\u00e5llberg","year":"2011","journal-title":"J. Nucl. Med."},{"key":"2026081907205019300_cit23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189068","article-title":"Generation\nof Ca2+-independent sortase A mutants with enhanced activity for protein\nand cell surface labeling","volume":"12","author":"Jeong","year":"2017","journal-title":"PLoS One"},{"issue":"21\u201322","key":"2026081907205019300_cit24","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.drudis.2012.07.002","article-title":"Liver uptake of radiolabeled targeting\nproteins and peptides: considerations for targeting peptide conjugate\ndesign","volume":"17","author":"Hosseinimehr","year":"2012","journal-title":"Drug Discovery Today"},{"issue":"7","key":"2026081907205019300_cit25","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","article-title":"Renal toxicity of radiolabeled peptides and antibody\nfragments: mechanisms, impact on radionuclide therapy, and strategies\nfor prevention","volume":"51","author":"Vegt","year":"2010","journal-title":"J. Nucl. Med."},{"issue":"17","key":"2026081907205019300_cit26","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29173993","article-title":"Differences in the\nRenal Accumulation of Radiogallium-Labeled (Glu)14 Peptides\nContaining Different Optical Isomers of Glutamic Acid","volume":"29","author":"Ogawa","year":"2024","journal-title":"Molecules."},{"issue":"11","key":"2026081907205019300_cit27","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1021\/acs.bioconjchem.4c00413","article-title":"eSOMA-DM1,\na Maytansinoid-Based Theranostic\nSmall-Molecule Drug Conjugate for Neuroendocrine Tumors","volume":"35","author":"Chapeau","year":"2024","journal-title":"Bioconjugate Chem."},{"issue":"1","key":"2026081907205019300_cit28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1021\/acs.molpharmaceut.9b00788","article-title":"Cellular Delivery\nof\nBioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate\nCancer","volume":"17","author":"Hapuarachchige","year":"2020","journal-title":"Mol. Pharm."},{"issue":"8","key":"2026081907205019300_cit29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081168","article-title":"Incorporation of a\nHydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1\nDrug Conjugates","volume":"11","author":"Ding","year":"2019","journal-title":"Cancers"},{"issue":"2","key":"2026081907205019300_cit30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1021\/acs.bioconjchem.4c00392","article-title":"PEGylation\nof Dipeptide Linker Improves Therapeutic Index and Pharmacokinetics\nof Antibody-Drug Conjugates","volume":"36","author":"Long","year":"2025","journal-title":"Bioconjugate Chem."},{"key":"2026081907205019300_cit31","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.apradiso.2006.03.002","article-title":"Automated, high-resolution cellular retention and uptake\nstudies in vitro","volume":"64","author":"Bjo\u0308rke","year":"2006","journal-title":"Appl. Radiat. Isot."},{"key":"2026081907205019300_cit32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1089\/cbr.2008.0464","article-title":"Slow internalization\nof anti-HER2 synthetic affibody\nmonomer 111In-DOTA-ZHER2:342-pep2: implications for development of\nlabeled tracers","volume":"23","author":"W\u00e5llberg","year":"2008","journal-title":"Cancer Biother. Radiopharm."}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.6c00035","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/8\/1562\/66341148\/acs.bioconjchem.6c00035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/8\/1562\/66341148\/acs.bioconjchem.6c00035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:55:01Z","timestamp":1787140501000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/37\/8\/1562\/5237372\/Peptide-Nucleic-Acid-Probes-for-Pretargeted"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,7,30]]},"published-print":{"date-parts":[[2026,8,19]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00035","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}